A proven, rapidly growing producer of complex drug delivery systems.

Nemera designs and manufactures a full range of drug delivery systems including asthma inhalers, insulin pens, auto-injectors and nasal pumps.

The Nemera Group originally comprised two businesses at acquisition in May 2014: a healthcare devices business (Nemera) as well as a prescription retail containers and closures business (Centor, which was sold in 2015), both carved-out of Rexam plc.  

In October 2018, we reinvested in Nemera alongside another investor to support the next phase of Nemera’s growth.

0

Core drug delivery verticals

00

Sales growth 2014-2018

0

World-class manufacturing sites

A Montagu business

  • Strong and highly capable management team
  • Market leading positions in multiple drug delivery verticals
  • High revenue visibility with both organic and inorganic growth opportunities

 

Growing Nemera’s reach

Following Nemera’s achievements since 2014, the current strategy focuses on organic and acquisitive growth so that Nemera reaches its potential as a leader in its different markets and geographies.

To add to its existing product research and development capabilities, in August 2019 Nemera acquired US medical device developer Insight Product Development.  Nemera subsequently rebranded and relaunched the Company’s combined development arm as the “Insight Innovation Center”, which has enabled the business to pursue opportunities from multiple pre-production design phases.

Our first partnership

Between 2014 and 2018, we supported Nemera in:

  • Quickly selling Centor, unlocking immediate value
  • Executing a holistic value creation plan, which included the introduction of a new reporting structure and a sales team reorganisation that supported sales growth
  • Streamlining Nemera’s manufacturing footprint, which substantially increased margins

 

Deal details


Year of entry

2018


Country

France


Status

In portfolio


Industry Sector

Healthcare

Back to all portfolio